Obesity as a long-term disease and the important role of new treatments

The introduction of GLP-1 receptor agonists has transformed obesity management by producing substantial weight reduction.

• Obesity is now recognized as a chronic, progressive disease with major health complications.
• Traditional lifestyle interventions and older medications often lead to modest and temporary weight loss.
• GLP-1 receptor agonists, including liraglutide and semaglutide, significantly improve weight loss and reduce risks of diabetes and cardiovascular disease.
• Tirzepatide, a dual GIP/GLP-1 agonist, shows weight loss effects comparable to metabolic surgery and promising cardiometabolic improvements.
• Long-term use of these therapies is necessary to prevent weight regain and increased cardiovascular risk after discontinuation.

Simplified